AU2003276822A1 - Lactobacilli expressing biologically active polypeptides and uses thereof - Google Patents

Lactobacilli expressing biologically active polypeptides and uses thereof

Info

Publication number
AU2003276822A1
AU2003276822A1 AU2003276822A AU2003276822A AU2003276822A1 AU 2003276822 A1 AU2003276822 A1 AU 2003276822A1 AU 2003276822 A AU2003276822 A AU 2003276822A AU 2003276822 A AU2003276822 A AU 2003276822A AU 2003276822 A1 AU2003276822 A1 AU 2003276822A1
Authority
AU
Australia
Prior art keywords
biologically active
active polypeptides
expressing biologically
lactobacilli expressing
lactobacilli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003276822A
Other versions
AU2003276822A8 (en
Inventor
Chia-Hwa Chang
John A. Lewicki
Theresa Li-Yun Chang
David A. Simpson
Qiang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osel Inc
Original Assignee
Osel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osel Inc filed Critical Osel Inc
Publication of AU2003276822A1 publication Critical patent/AU2003276822A1/en
Publication of AU2003276822A8 publication Critical patent/AU2003276822A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003276822A 2002-03-08 2003-03-06 Lactobacilli expressing biologically active polypeptides and uses thereof Abandoned AU2003276822A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36294502P 2002-03-08 2002-03-08
US60/362,945 2002-03-08
PCT/US2003/007233 WO2004007695A2 (en) 2002-03-08 2003-03-06 Lactobacilli expressing biologically active polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2003276822A1 true AU2003276822A1 (en) 2004-02-02
AU2003276822A8 AU2003276822A8 (en) 2004-02-02

Family

ID=30115465

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003276822A Abandoned AU2003276822A1 (en) 2002-03-08 2003-03-06 Lactobacilli expressing biologically active polypeptides and uses thereof

Country Status (3)

Country Link
US (3) US7179458B2 (en)
AU (1) AU2003276822A1 (en)
WO (1) WO2004007695A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007695A2 (en) * 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
WO2005012491A2 (en) * 2003-01-29 2005-02-10 Osel, Inc. Surface expression of biologically active proteins in bacteria
EP1786445B1 (en) * 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Live microbial microbicides
WO2006083516A2 (en) * 2005-01-12 2006-08-10 Osel, Inc. Modified cyanovirin-n polypeptide
US8038990B2 (en) * 2005-06-01 2011-10-18 The Ohio State University Compositions and methods for the prevention and removal of biofilms on inert and biological surfaces
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
US20090305089A1 (en) * 2006-07-14 2009-12-10 Akermin, Inc. Organelles in bioanodes, biocathodes, and biofuel cells
DK3156414T3 (en) * 2007-09-26 2020-03-09 Intrexon Corp SYNTHETIC 5'PRESE EXPRESSION VECTORS AND METHODS FOR INCREASING TRANSGENIC EXPRESSION
US20110150907A1 (en) * 2008-04-04 2011-06-23 Farallone Holdings Bv Methods and materials for gastrointestinal delivery of pathogen/toxin binding agents
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
CN102329766A (en) * 2011-09-16 2012-01-25 暨南大学 Recombination food-grade lactic acid bacterium capable of being used for preventing or treating human ulcerative colitis as well as preparation method and application of recombination food-grade lactic acid bacterium
MX367136B (en) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Novel highly-specified polyvalent immunotherapeutic drugs based on modified antibodies and highly-secure and effective injectable lyophilized formulation.
EP4023750A1 (en) * 2013-07-01 2022-07-06 Massachusetts Institute of Technology Functionalization of endogenous bacteria
WO2015116531A1 (en) * 2014-01-29 2015-08-06 Synphagen Llc. Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
US10351452B2 (en) * 2014-01-29 2019-07-16 Synphagen Llc Compositions for in vivo expression of therapeutic sequences in the microbiome
EP3158054A4 (en) 2014-06-17 2017-11-15 Xycrobe Therapeutics Inc. Genetically modified bacteria and methods for genetic modification of bacteria
US20190315642A1 (en) * 2016-07-27 2019-10-17 Synphagen Llc Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome
WO2017058175A1 (en) 2015-09-29 2017-04-06 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018183685A1 (en) 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
CN110709093A (en) * 2017-04-17 2020-01-17 加利福尼亚大学董事会 Engineered bacteria and methods of use
US11530433B2 (en) 2017-10-20 2022-12-20 President And Fellows Of Harvard College Artificial secretion peptides for heterologous protein production
CN112220739B (en) * 2020-10-15 2023-09-01 国润生物科技（深圳）有限公司 HPV virus inactivation dressing and preparation method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6180100B1 (en) 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
IT1270123B (en) 1994-10-05 1997-04-28 Dompe Spa PHARMACEUTICAL COMPOSITIONS CONTAINING ENGINEERED MICROORGANISMS AND THEIR USE FOR THERAPY
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6193982B1 (en) * 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6160100A (en) * 1997-03-27 2000-12-12 Univ Toronto Treatment for wilt diseases of trees
US6093394A (en) * 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
ATE207755T1 (en) 1998-04-30 2001-11-15 Vesely Renata Maria Cavaliere PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILLUS BREVIS AND LACTOBACILLUS SALIVARIUS FOR THE TREATMENT OF VAGINAL INFECTIONS
US6060027A (en) 1998-05-14 2000-05-09 Fantom Technologies Inc. Ozone generator
AU4228699A (en) * 1998-06-03 1999-12-20 Northwestern University Cellular proteins which mediate herpesvirus entry
WO2004007695A2 (en) * 2002-03-08 2004-01-22 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
WO2006083516A2 (en) * 2005-01-12 2006-08-10 Osel, Inc. Modified cyanovirin-n polypeptide

Also Published As

Publication number Publication date
US20030228297A1 (en) 2003-12-11
AU2003276822A8 (en) 2004-02-02
US7179458B2 (en) 2007-02-20
WO2004007695A2 (en) 2004-01-22
US7312076B2 (en) 2007-12-25
WO2004007695A3 (en) 2005-04-07
US20090148408A1 (en) 2009-06-11
US20070117197A1 (en) 2007-05-24
US7833791B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
AU2003276822A1 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
AU2003286472A1 (en) Microencapsulation and sustained release of biologically active polypeptides
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
AU2002357643A1 (en) The human mob-5 (il-24) receptors and uses thereof
AU2003254950A1 (en) Peptides and drugs containing the same
AU2003228489A1 (en) Biocompatible materials and probes
AU2003276937A1 (en) Vegetable protein preparations and use thereof
AU2003280918A1 (en) Rabbit skin comprising biological active substance and its use
AU2003274900A1 (en) Cellular reprogramming in peptide hydrogel and uses thereof
AU2003215257A1 (en) Modified defensins and their use
AU2003285270A1 (en) Intermetallic material and use of said material
AU2003295107A1 (en) Biological control agent and formulations
AUPS238502A0 (en) Cystic echinococcosis protein and uses therefor
AU2003207628A1 (en) Structural and cytoskeleton-associated proteins
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2002230129A1 (en) Novel physiologically active peptide and use thereof
AU2003298441A1 (en) Biological control agent and formulations
AU2003293500A1 (en) Lactoferrin in the reduction of pain
AU2001280464A1 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
AU2003277583A1 (en) Physiologically active polypeptide and its antibody and use thereof
AU2002951912A0 (en) Tryptase polypeptide and uses thereof
AU2003261900A1 (en) Method of designing physiologically active peptide and use thereof
AU2003216442A1 (en) Enkurin and uses thereof
AU2003303464A1 (en) Centrosome-associated protein and applications thereof
AU2003262895A1 (en) Carboxypeptidase b related polypeptides and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase